{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:25:01Z","timestamp":1787901901450,"version":"build-2784847793"},"reference-count":21,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,15]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>MRD negativity is a predictor for long-term progression-free and overall survival independent of the type and line of therapy. MRD negativity confers the greatest prognostic benefit when achieved in the frontline setting.<\/jats:p>","DOI":"10.1182\/blood-2016-05-714162","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T23:19:20Z","timestamp":1475536760000},"page":"2770-2773","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["Minimal residual disease is an independent predictor for 10-year survival in CLL"],"prefix":"10.1182","volume":"128","author":[{"given":"Marwan","family":"Kwok","sequence":"first","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"},{"name":"Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy C.","family":"Rawstron","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Varghese","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A. S.","family":"Evans","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila J. M.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Doughty","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren J.","family":"Newton","sequence":"additional","affiliation":[{"name":"Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moreton","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111903354516300_B1","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111903354516300_B2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2019111903354516300_B3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111903354516300_B4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"issue":"13","key":"2019111903354516300_B5","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111903354516300_B6","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111903354516300_B7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-07-1371","article-title":"Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication","volume":"14","author":"Bosch","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2019111903354516300_B8","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111903354516300_B9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111903354516300_B10","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111903354516300_B11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","article-title":"Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial","volume":"30","author":"Pettitt","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111903354516300_B12","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2019111903354516300_B13","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111903354516300_B14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3324\/haematol.2013.099796","article-title":"The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy","volume":"99","author":"Santacruz","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2019111903354516300_B15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111903354516300_B16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2019111903354516300_B17","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"7574","key":"2019111903354516300_B18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"17","key":"2019111903354516300_B19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111903354516300_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.830.830","article-title":"Deep and durable responses following venetoclax (ABT-199 \/ GDC-0199) combined with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia: results from a phase 1b study [abstract]","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111903354516300_B21","article-title":"Venetoclax (ABT-199\/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed\/refractory chronic lymphocytic leukemia with 17p deletion: results of the Pivotal International Phase 2 Study [abstract]","volume":"126","author":"Eichhorst","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/24\/2770\/1358282\/blood714162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/24\/2770\/1358282\/blood714162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:35:56Z","timestamp":1574134556000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/24\/2770\/35975\/Minimal-residual-disease-is-an-independent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":21,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-05-714162","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726814834.793538191","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}